---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-047582"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2026-10-19T20:05:22+00:00"
generated_at: "2026-10-19T20:06:07.863990+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Glucotrack issues 406,198 new warrants at $7.50 after holders waive issuance and VRT restrictions

## Summary
- Glucotrack's Oct. 13, 2026 waiver with Requisite Holders ends the 90-day equity issuance restriction and warrant variable-rate price adjustment from the July 14, 2026 purchase agreement.
- In exchange, Glucotrack will issue New Warrants for 406,198 common shares at $7.50 per share; they expire in five years and carry a 9.99% beneficial ownership cap.
- The New Warrants are not exercisable until stockholders approve the Warrant Shares under Nasdaq Listing Rule 5635; the exercise price has customary adjustments with a 20% closing-price floor.
- The equity-issuance waiver covers all Holders, while the variable-rate exercise-price waiver applies only to Existing Warrants held by Holders that signed; other transaction documents remain in force.

## SEC filing metadata
- accession: 0001493152-26-047582
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2026-10-19T20:05:22+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315226047582/0001493152-26-047582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315226047582/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-047582
- JSON: https://secwatch.observer/filing/0001493152-26-047582.json
- Plain text: https://secwatch.observer/filing/0001493152-26-047582.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.